NPM1 and acute myeloid leukemia: The prognostic effect of TET2 is unclear with some studies showing an inferior survival in AML with a normal karyotype, especially those with favorable genetic mutations (isolated CEBPA and NPM1), and other studies showing no effect [18,29,54,55].